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Abstract
Background: Because cardiomyopathy is the leading cause of death in diabetic patients, the
determination of myocardial function in diabetes mellitus is essential. In the present study, we
provide an integrated approach, using noninvasive echocardiography and invasive hemodynamics to
assess early changes in myocardial function of diabetic rats.
Methods: Diabetes was induced by streptozotocin injection (STZ, 50 mg/kg). After 30 days,
echocardiography (noninvasive) at rest and invasive left ventricular (LV) cannulation at rest, during
and after volume overload, were performed in diabetic (D, N = 7) and control rats (C, N = 7). The
Student t test was performed to compare metabolic and echocardiographic differences between
groups at 30 days. ANOVA was used to compare LV invasive measurements, followed by the
Student-Newman-Keuls test. Differences were considered significant at P < 0.05 for all tests.
Results: Diabetes impaired LV systolic function expressed by reduced fractional shortening,
ejection fraction, and velocity of circumferential fiber shortening compared with that in the control
group. The diabetic LV diastolic dysfunction was evidenced by diminished E-waves and increased
A-waves and isovolumic relaxation time. The myocardial performance index was greater in diabetic
compared with control rats, indicating impairment in diastolic and systolic function. The LV systolic
pressure was reduced and the LV end-diastolic pressure was increased at rest in diabetic rats. The
volume overload increased LVEDP in both groups, while LVEDP remained increased after volume
overload only in diabetic rats.
Conclusion: These results suggest that STZ-diabetes induces systolic and diastolic dysfunction at
rest, and reduces the capacity for cardiac adjustment to volume overload. In addition, it was also
demonstrated that rodent echocardiography can be a useful, clinically relevant tool for the study
of initial diabetic cardiomyopathy manifestations in asymptomatic patients.
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Background
Diabetes is a chronic metabolic disorder associated with
secondary complications in the cardiovascular system and
autonomic control in humans and animals [1-4]. Diabetic
cardiomyopathy, a myopathic state independent of mac-
rovascular complications, is the leading cause of death in
diabetic patients [2]. Diabetic cardiomyopathy was impli-
cated when diabetic patients at preclinical stages were
found to exhibit a shortened left ventricular ejection time,
a longer pre-ejection period, and elevated end-diastolic
pressure [5]. However, the time-course of diabetic cardio-
myopathy is still controversial, because reports have
shown myocardial dysfunction at different times in the
disease process.
Different methodologies have been used to investigate
systolic and diastolic function in diabetic patients and
rats. Assessment of cardiac function in experimental dia-
betes has relied on ex vivo [3] or in vivo [6-8] techniques.
The ex vivo technique requires sacrifice of the animals and
is devoid of autonomic reflexes and ventricular-vascular
coupling. Although LV cannulation is a well-established,
precise invasive method, not devoid of autonomic reflexes
and ventricular-vascular coupling, this technique is lim-
ited because of the difficulty in keeping a catheter in the
left ventricle throughout the long study period, and it is
not without risk and does not allow assessment of the
time course of cardiovascular changes. On the other hand,
echocardiography has been used in several studies to
demonstrate the time course of cardiovascular changes for
different pathologies [9-12]. It is well established that
clinically apparent diabetic cardiomyopathy may take sev-
eral years to develop, but echocardiography can detect sig-
nificant abnormalities early at the onset of symptomatic
heart failure. Although several studies have used echocar-
diography as one noninvasive methodology to identify
cardiac dysfunction associated with diabetes mellitus, no
previous studies have used one integrated approach, ie,
echocardiography and in vivo hemodynamics, to evaluate
cardiac function in an experimental diabetes model. So
the purpose of the present study was characterization of
early myocardial dysfunction performed at the same time
by noninvasive echocardiography and invasive LV cathe-
terization in STZ-induced diabetic rats.
Methods
Male Wistar rats (230 – 260 g) were obtained from the
animal facilities at the University of São Paulo Medical
School, São Paulo, Brazil. The rats received standard labo-
ratory chow and water ad libitum. They were housed in
individual cages in a temperature-controlled room
(22°C) with a 12-h dark-light cycle. All procedures and
protocols used were in accordance with the Guidelines for
Ethical Care of Experimental Animals and were approved
by the International Animal Care and Use Committee.
Experimental diabetic model
The rats were randomly assigned to 1 of 2 groups: control
(C, N = 7), diabetic (D, N = 7). Animals were made dia-
betic by a single injection of STZ (50 mg/Kg, iv; Sigma
Chemical Co., St. Louis, MO, USA) dissolved in citrate
buffer, pH 4.5. Food was withheld from the rats for 6
hours before STZ injection. Control rats received a pla-
cebo (10 mM citrate buffer, pH 4,5) after a similar fasting
period.
Twenty-four hour urine was collected 29 days after diabe-
tes induction. Animals were placed in a metabolic cage
and were allowed free access to food and water during the
collection period. Urine was collected and centrifuged at
1,000 g for 10 minutes to remove particles, and the vol-
ume was recorded. Urine samples were stored at -20°C for
biochemistry analysis (Cobas Integra 700-Roche, Swiss).
Noninvasive evaluation of cardiac function
Echocardiographic indices were obtained according to the
recommendations of the American Society of Echocardi-
ography. Transthoracic echocardiography was performed
in control and diabetic animals at 30 days, by double-
blind observers with the use of a SEQUOIA 512 (ACU-
SON Corporation, Mountain View, CA), which offers a
10–13 MHz multifrequency linear transducer. Images
were obtained with the transducer on each animal's
shaved chest (lateral recumbence). To optimize the image,
a transmission gel was used between the transducer and
the animal's chest (General Imaging Gel, ATL. Reedsville,
PA, USA). Animals were scanned from below, at a 2-cm
depth with focus optimized at 1 cm. All measurements
were based on the average of 3 consecutive cardiac cycles.
Rats were anesthetized with a combination of ketamine
hydrochloride 50 mg/kg and xylazine 10 mg/kg IP. Wall
thickness and LV dimensions were obtained from a short-
axis view at the level of the papillary muscles. LV mass was
calculated by using the following formula, assuming a
spherical LV geometry and validated in rats: LV mass =
1,047 × [(LVd+PWd+IVSd)3 - LVd3], where 1,047 is the
specific gravity of muscle, LVd is LV end-diastolic diame-
ter, PWd is end-diastolic posterior wall thickness and IVSd
is end-diastolic interventricular septum thickness. In addi-
tion, another index of morphology was evaluated, the rel-
ative wall thickness (RWT), which is expressed by 2 ×
PWD/LVd. It represents the relation between the LV cavity
in diastole and the LV posterior wall. LV fractional short-
ening was calculated as (LVd-LVs)/LVd × 100, where LVs
is LV end-systolic diameter. Two-dimensional guided
pulsed-wave Doppler recordings of LV inflow were
obtained from the apical 4-chamber view. Maximal early
diastolic peak velocity (E) and late peak velocity (A) were
derived from mitral inflow. The LV outflow tract velocity
was measured just below the aortic valve, from an apical
5-chamber view. The velocity of circumferential fiber
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shortening (VCF) was measured following the formula
(LVd-LVs)/(LVd × ET), where ET is the ejection time. The
sample volume was then placed between the mitral valve
and LV outflow tract so that the aortic valve closure line
and the onset of mitral flow could be clearly identified.
Isovolumic relaxation time (IVRT) was taken from aortic
valve closure to the onset of mitral flow. Global cardiac
function was evaluated by using the Myocardial Perform-
ance Index (MPI), which is the ratio of total time spent in
isovolumic activity (isovolumic contraction time and iso-
volumic relaxation time) to the ejection time (ET). These
Doppler time intervals were measured from the mitral
inflow and LV outflow time intervals. Interval "a", from
the cessation to onset of mitral inflow, is equal to the sum
of the isovolumic contraction time, ET and isovolumic
relaxation time. Ejection time "b" is derived from the
duration of the LV outflow Doppler velocity profile. The
MPI was calculated with the formula (a-b)/b.
Invasive evaluation of cardiac function
LV function was measured also invasively in anesthetized
rats (pentobarbital sodium, 40 mg/Kg). One catheter of
PE-50 was inserted into the right carotid artery and
advanced into the LV, and a second catheter of PE-50 was
inserted into the jugular vein for saline and drug adminis-
tration. Ventricular pressure signals were measured with a
transducer and conditioner (Hewlett Packard 8805C,
Waltham, MA) and digitally recorded (5 min) with a data
acquisition system (WinDaq, 2-kHz, DATAQ, Springfield,
OH). The recorded data were analyzed on a beat-to-beat
basis to quantify changes in LV pressure. The following
indices were obtained: heart rate (HR), LV systolic pres-
sure (LVSP), LV end-diastolic pressure (LVEDP), and max-
imum rate of LV pressure rise and fall (+dP/dt max and -
dP/dt max). After LV pressure basal records, the LV func-
tion was recorded during a volume overload protocol per-
formed by an injection of saline (0.27 mL/min/kg) during
3 minutes adapted from Souza's study [13]. According to
the volume overload protocol, the restoration of LV
parameters was measured there for 3 minutes.
Data are reported as means ± SEM, and the Student t test
was performed to compare metabolic and echocardio-
graphic differences between different groups. Two-way
ANOVA was used to compare LV invasive measurements,
followed by the Student-Newman-Keuls test. Differences
were considered significant at P < 0.05 for all tests.
Results
Rats treated with STZ not only developed hyperglycemia
(340 ± 7.6 vs. 87 ± 10 mg/dL, D vs. C, P < 0.0001) but also
polydipsia (172 ± 6.5 vs. 40 ± 7 mL/24 h, D vs. C, P <
0.0001), polyuria (125 ± 4.4 vs. 9 ± 0.7 mL/24 h, D vs. C,
P < 0.0001), glucosuria (12 ± 0.5 vs. 0.0026 ± 0.0003 mg/
dL, D vs. C, P < 0.0001), proteinuria (0.02 ± 0.002 vs. 0.01
± 0.0009 mg, D vs. C, P < 0.0001), and uremia (1.6 ± 0.09
vs. 0.27 ± 0.03 mg, D vs. C, P < 0.0001). Body weight was
reduced in the diabetic group (270 ± 8 g) compared with
weight in the control group (360 ± 11 g, P < 0.0001).
Noninvasive evaluation of cardiac function
Echocardiography 30 days after STZ demonstrated that LV
internal dimension (cm) during diastole increased (0.73
± 0.03 vs. 0.63 ± 0.03, D vs. C, P < 0.05), and the thickness
of the interventricular septum and of the posterior wall
during diastole decreased (0.101 ± 0.003 vs. 0.138 ±
0.005 and 0.1 ± 0.003 vs. 0.138 ± 0.005, D vs. C, P <
0.001, respectively) in diabetic rats in relation to control
rats. RWT was significantly lower in diabetic (0.27 ±
0.016) than in control rats (0.40 ± 0.01, P < 0.05). LV
systolic function, as expressed by fractional shortening
(%) (34 ± 3.7 vs. 39 ± 3.7, D vs. C, P < 0.05), ejection frac-
tion (%) (69 ± 0.02 vs. 75.4 ± 0.015, D vs. C, P < 0.05) and
VCF (circ/sec) (0.003 ± 0.0002 vs. 0.004 ± 0.0003, D vs.
C, P < 0.01) was reduced in diabetic group compared with
that in the control group. LV diastolic function was
observed after 30 days of STZ-induced diabetes, as
expressed by reduced E-wave (m/s) (0.44 ± 0.036 vs 0.53
± 0.04, D vs. C, P < 0.05) and increased A-wave (m/s) (0.4
± 0.04 vs. 0.33 ± 0.02, D vs. C, P < 0.05) in diabetic ani-
mals when compared with control animals. The diabetic
group had a reduced E/A ratio (1.33 ± 0.09) compared
with the control group (1.62 ± 0.07, P < 0.05). Decelera-
tion time of E-wave (EDT, ms) (39 ± 1.3 vs. 30 ± 1.7, D vs.
C, P < 0.0001) and IVRT (ms) (40.6 ± 1.65 vs. 31.6 ± 1.5,
D vs. C, P < 0.05) were increased in the diabetic group
compared with the control group, reflecting early diastolic
dysfunction by slow relaxation. Statistical comparison of
normalized EDT and IVRT by HR during echocardiogra-
phy corroborated differences between groups observed
using their absolute values. MPI was greater in the diabetic
group (0.41 ± 0.014) compared with that in the control
group (0.29 ± 0.054, P < 0.0001).
Invasive evaluation of cardiac function
As can be seen in Table 1, invasive measurements of car-
diac function by LV cannulation demonstrate systolic and
diastolic impairment at rest and during and after a volume
overload protocol in diabetic rats compared with that in
control rats. Figure 1 shows an original basal record of LV
pressure and +dP/dt max and -dP/dt max of LV pressure in
a control rat and a diabetic rat. The diabetic group had a
reduction in LVSP (17%) and in HR (14%) in relation to
the control group at baseline. The LVEDP, an index of
congestive heart failure, showed a significant increase
(57%) in diabetic rats compared with that in controls at
baseline. Resting maximum rates of rise (+dP/dt max) and
fall (-dP/dt max) in LV pressure were also impaired after
diabetes.
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During and after volume overload, the differences in LV
function between groups remained the same as in the
baseline period. However, the LVEDP increased in both
groups during and after volume overload compared with
their respective baseline values. Only diabetic rats showed
an increase in LVEDP values in the post volume overload
period in relation to LVEDP values during the volume
overload period (Table 1).
Discussion
The present study provides an integrated approach to the
assessment of diabetic cardiac function in rats, using both
noninvasive echocardiography and invasive hemody-
namic evaluation; it provides important new insights into
the pathophysiology of diabetic cardiomyopathy. The
present data confirm our preliminary findings that STZ
diabetes induces hyperglycemia, weight loss, and brady-
cardia. However, the major finding of this study is that
rats with 30 days of STZ-induced-diabetes had impair-
ment in cardiac structure and function as evidenced non-
invasively by echocardiography and invasively by LV
catheterization, and also that this LV dysfunction was
exacerbated by volume overload.
Noninvasive evaluation of cardiac function
Echocardiographic measurements of cardiac function and
structure in the present experiments demonstrated both
LV systolic and diastolic dysfunction in 30-day diabetic
rats. In fact, several investigators have shown abnormali-
ties in LV systolic function, diastolic function, and com-
plaints in humans [10-12] and rats [9,14-16], by using a
noninvasive method of evaluation. Joffe et al [7] observed
diabetic cardiomyopathy, characterized by LV systolic and
diastolic dysfunction, after two and a half months of STZ
in rats. Akula et al [9] in a recent study used echocardiog-
raphy to examine LV function in STZ rats over a definite
course of time (2, 4, 8, and 12 weeks). They concluded
that LV systolic and diastolic dysfunction was fully visible
at 12 weeks of diabetes by this method, and that echocar-
diography is useful in diagnosing cardiac abnormalities in
diabetic rats without the need for invasive histopatholog-
ical procedures. In contrast with these authors, we
observed systolic and diastolic dysfunction after 30 days
of STZ-induced diabetes documented by reduced ejection
fraction, fractional shortening, and E-wave and increased
A-wave and EDT, as well as by reduced VCF and increased
IVRT observed in diabetic animals compared with con-
trols. Corroborating our data, Yu et al [17] observed sig-
nificant deficits in myocardial morphology and
functionality by using magnetic resonance imaging at 4
weeks of diabetes in STZ-induced diabetic mice. In
another study, Mihm et al [14] showed reductions in HR
and EDT after 3 days of STZ-induced diabetes, and these
reductions progressed throughout the 56-day period. Fur-
thermore, these authors observed that systolic dysfunc-
tion was detected only after 35 days of study.
LV cavity dilatation accompanied by no changes in wall
thickness has been observed previously after 35 and 75
days [7,14] and 12 weeks [9] of diabetes. Joffe et al [7]
demonstrated not only LV cavity dilatation, but also
increased LV mass after 75 days of STZ induction in rats,
suggesting evidence of cardiomyopathy characterized by
eccentric hypertrophy. In contrast, in the present study,
we observed LV cavity dilatation accompanied by
decreased thickness of the LV posterior wall and interven-
Table 1: Left ventricular function at baseline, during, and after volume overload in the control and diabetic groups.
Parameter Group (n = 7) BASELINE VOLUME OVERLOAD POST VOLUME OVERLOAD
1 min 2 min 3 min 1 min 2 min 3 min
LVSP C 136 ± 4.7 125 ± 6.5 135 ± 7 134 ± 6 139 ± 7.8 134 ± 8.8 138 ± 6
(mm Hg) D 114 ± 6* 116 ± 5.8* 112 ± 5 * 114 ± 6 * 107 ± 10 * 102 ± 4 * 107 ± 10*
LVEDP C 4.6 ± 0.3 7.8 ± 0.6 8.0 ± 0.6 9.1 ± 0.56 11 ± 1.3 9 ± 1.1 9.4 ± 1.1
(mm Hg) D 7.4 ± 0.2* 9.9 ± 0.5*# 12.3 ± 0.55*# 11.5 ± 0.72*# 17 ± 1.3 *#† 16 ± 0.7 *#† 15 ± 1.1 *#†
HR C 350 ± 14 327 ± 10 333 ± 11.5 340 ± 7.5 352 ± 5 360 ± 6 360 ± 6
(beats/min) D 307 ± 8.5* 300 ± 6 * 300 ± 7* 302 ± 7* 297 ± 1.5* 298 ± 2* 294 ± 3.5 *
+dP/dt max C 9229 ± 463 8052 ± 741 8699 ± 653 8595 ± 457 8858 ± 504 9273 ± 569 9264 ± 603
(mm Hg/sec) D 6566 ± 609 * 5861 ± 584 * 5760 ± 770 * 6087 ± 1017* 5320 ± 1287 * 5844 ± 1217* 5712 ± 1247*
-dP/dt max C -6845 ± 379 -6446 ± 576 -6543 ± 600 -6139 ± 514 -6672 ± 646 -6320 ± 858 -6272 ± 707
(mm Hg/sec) D -4746 ± 589* -4804 ± 580* -4678 ± 580* -4152 ± 694* -3706 ± 614 * -3557 ± 561* -3246 ± 653*
Data are reported as means ± SEM; LVSP: left ventricle systolic pressure; HR: heart rate; LVEDP: left ventricle end diastolic pressure; +dP/dt max: 
maximum rate of left ventricle pressure rise; -dP/dt max: maximum rate of left ventricle pressure fall; C: control group; D: diabetic group. * P ≤ 0.05 
vs. controls; #P < 0.05 vs. baseline values; † P < 0.05 vs. volume overload values (2-way ANOVA).
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tricular septum after 30 days of diabetes, suggesting a
reduction in LV mass. Similarly, Dobrzynki et al [18]
observed reduced heart weight and LV mass associated
with cardiac and renal function damage after 21 days of
STZ-induced diabetes in rats. In addition, our study is the
first to describe the RWT reduction in diabetic rats, indi-
cating a probable reduction in LV mass, as previously
demonstrated [19].
MPI is a simple and nongeometric index that combines
systolic and diastolic functions independently of heart
rate, not requiring frequency based normalization [20].
The importance of MPI in this study is that it is an HR-
independent measure unlike transmitral flow velocities.
MPI also has not been used previously to investigate car-
diomyopathy in diabetic rats. In our evaluations, MPI was
increased in diabetic rats, suggesting global cardiac dys-
function in these animals. This result appears to correlate
well with invasive measurements of systolic and diastolic
measurements in humans [20] and animals [21].
Recently, MPI was validated in mice, and is strongly corre-
lated with invasive measurements of the LV dP/dt max
[21]. MPI has a prognostic value after myocardial infarc-
tion [22], as well as in adults with amyloidosis [23] and
dilated cardiomyopathy [24], and is not affected by mitral
regurgitation [25].
Invasive evaluation of cardiac function
Dent et al [16] demonstrated that differences in diastolic
function might be noninvasively quantified in diabetic
hearts; however, these authors recognized that the lack of
in vivo hemodynamic data was one limitation of their
Left ventricle cavity (a), E-wave (EW, b), A-wave (AW, b), original record of basal left ventricle pressure (c), and +dP/dt max and -dP/dt max of left ventricl pressure (d) in control and diabetic ratsFigur  1
Left ventricle cavity (a), E-wave (EW, b), A-wave (AW, b), original record of basal left ventricle pressure (c), and +dP/dt max 
and -dP/dt max of left ventricle pressure (d) in control and diabetic rats.
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study. In our experiments, direct measurements of cardiac
function corroborate diastolic and systolic LV function
impairment observed after 30-day-induced diabetes by
the echocardiographic approach. In vivo LV function evi-
denced reduced LVSP and +dP/dt max, reflecting a systolic
dysfunction, increased LVEDP and attenuated -dP/dt max,
showing diastolic dysfunction. These data associated with
the impairment in MPI reported in the diabetic group in
the present study corroborate the positive correlation
between these ventricular indexes, as previously shown in
mice [21]. In fact, similar alterations in LVEDP, contractil-
ity, bradycardia, reduced cardiac output, and renal dam-
age were evidenced after 21 days of STZ in rats. Reduction
in HR in diabetic rats has been attributed to changes in
sinoatrial node [1,3,26], although functional alterations
in the cholinergic mechanism cannot be excluded as a
causal factor. Joffe et al [7] showed the in vivo reduced
peak of LV systolic pressure and increased LVEDP, as well
as in vitro attenuation of LV +dP/dt max and -dP/dt max
after 75 days of STZ-induced diabetes in rats. Another
study in which in vivo LV cannulation was performed
showed a decrease in LV +dP/dt max and -dP/dt max after
15 days of STZ injection in rats [8]. Impairment in cardio-
vascular function in mice was also observed in diabetic-
infarcted mice at the same time point [27]. In a previous
study by our group, we reported that the isolated hearts of
11-week STZ-induced diabetic rats did not have differ-
ences in LV isovolumetric systolic pressure, but had
reduced contractility compared with isolated hearts in
control rats [3].
In addition, our results show impairment in cardiac
responses during and after volume overload in STZ-
induced rats. A similar increase in LVEDP observed in con-
trol rats in the present experiments was previously dem-
onstrated in the early stages of volume overload induced
by A-V fistula in control rats [28]. However, in contrast
with that observed in control rats, the high values of
recorded LVEDP in STZ-induced rats remained elevated
after volume overload, which may be explained by cardiac
changes produced by STZ. Despite the fact that LV cavity
dilatation allows major blood compliance, the reduced
fractional shortening, ejection fraction, and VCF observed
in STZ-induced rats are probably associated with the
increase in LVEDP during and after volume overload,
because the volume of blood can not be completely
ejected.
Studies that have examined both systolic and diastolic
dysfunction in diabetes suggest that the latter is more sus-
ceptible to preclinical changes. Diastolic dysfunction is
not just a defect in active relaxation, but also in passive
stiffness of the left ventricle [29]. The echocardiographic
evidence of subclinical contractile dysfunction and diasto-
lic filling abnormalities are predictive of subsequent
chronic heart failure [30]. Patients with diastolic heart
failure have an increased mortality of 5–8% compared
with the control group [31]. Systolic dysfunction occurs
late, often when patients have already developed signifi-
cant diastolic dysfunction. However, the prognosis in
patients with systolic dysfunction is an annual mortality
of 15–20%, greater than mortality in patients with diasto-
lic dysfunction [31]. Thus, the early detection of diastolic
and systolic dysfunction can prevent worsening of this
condition.
Conclusion
Using the STZ model of diabetes, we have demonstrated
that rodent echocardiography can be useful, because sen-
sitive changes in systolic and diastolic performance were
detected and markedly confirmed by in vivo direct LV
measurements. Changes reported in the present experi-
ments in cardiac performance are highly predictive of clin-
ical findings, and further illustrate the value of this model
of diabetic cardiomyopathy.
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